Identifying human rhinovirus with the syndromic testing approach
When a patient presents with severe cold-like or flu-like symptoms, it is impossible to know what’s causing the illness without diagnostic testing. That’s because many respiratory pathogens cause similar, overlapping symptoms. A child with severe respiratory symptoms, for example, could have human rhinovirus, COVID-19, influenza, respiratory syncytial virus, or another respiratory pathogen.
Syndromic infectious disease testing from BioFire can help deliver answers—fast. The BioFire Respiratory 2.1 (RP2.1) Panel identifies 22 of the most common respiratory pathogens, including human rhinovirus/enterovirus, with results in about 45 minutes. The BioFire RP2.1 Panel utilizes nasopharyngeal swabs, the CDC-recommended sample type for detection of upper respiratory tract infections.
For lower-tract infections, the BioFire® FilmArray® Pneumonia (PN) Panel identifies 33 clinically relevant targets, including bacteria, viruses, and antimicrobial resistance genes, in about an hour. The BioFire PN Panel zeros in on the lower respiratory tract by utilizing sputum (including endotracheal aspirate) or bronchoalveolar lavage (including mini-BAL) samples.
Fast and comprehensive results from either the BioFire RP2.1 Panel or the BioFire PN Panel can help inform rapid diagnosis and treatment decisions. Pneumonia patients, in particular, are often over-treated with antibiotics while clinicians await the results of diagnostic testing.6 Rapid answers can help avoid or reduce unnecessary antibiotics, while also enabling clinicians to make crucial decisions about admission, isolation, cohorting, and additional diagnostic testing.